Atorvastatin

Source: Wikipedia, the free encyclopedia.

Atorvastatin
Clinical data
Pronunciation/əˌtɔːrvəˈstætən/
Trade namesLipitor, others
AHFS/Drugs.comMonograph
MedlinePlusa600045
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)[2]
  • UK: POM (Prescription only)
  • US: ℞-only[3]
  • EU: Rx-only"Lipitor". European Medicines Agency. 17 September 2018. Retrieved 26 February 2023.</ref>
Pharmacokinetic data
Bioavailability12%
MetabolismLiver (CYP3A4)
Elimination half-life14 hours
ExcretionBile duct
Identifiers
  • (3R,5R)-7-[2-(4-Fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
JSmol)
  • O=C(O)C[C@H](O)C[C@H](O)CCn2c(c(c(c2c1ccc(F)cc1)c3ccccc3)C(=O)Nc4ccccc4)C(C)C
  • InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1 checkY
  • Key:XUKUURHRXDUEBC-KAYWLYCHSA-N checkY
  (verify)

Atorvastatin is a

by mouth.[4]

Common side effects include joint pain, diarrhea, heartburn, nausea, and muscle pains.[4] Serious side effects may include rhabdomyolysis, liver problems, and diabetes.[4] Use during pregnancy may harm the fetus.[4] Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in the liver that plays a role in producing cholesterol.[4]

Atorvastatin was patented in 1986, and approved for medical use in the United States in 1996.

generic medication.[4][7] In 2021, it was the most commonly prescribed medication in the United States, with more than 116 million prescriptions filled for over 28 million patients.[8][9]

Medical uses

The primary uses of atorvastatin is for the treatment of dyslipidemia and the prevention of cardiovascular disease:[10]

Dyslipidemia

Cardiovascular disease

A 2014 meta-analysis showed high-dose statin therapy was significantly superior compared to moderate or low-intensity statin therapy in reducing plaque volume in patients with acute coronary syndrome.[25] The SATURN trial which compared the effects of high-dose atorvastatin and rosuvastatin also confirmed these findings.[26] Despite the high dosage, the 40 mg pravastatin study arm in the REVERSAL trial failed to halt plaque progression, which suggests other factors such as which statin is used, duration and location of the plaque may also affect plaque volume reduction and thereby plaque-stabilization.[27] Overall, plaque reduction should be considered as a surrogate endpoint and should not be directly used to determine clinical benefit of therapy.[26][27] Increased risk of adverse events should also be taken into account when considering high-dose statin therapy.[25][26][27]

Kidney disease

There is evidence from systematic review and meta-analyses that statins, particularly atorvastatin, reduce both decline in kidney function (eGFR) and the severity of protein excretion in urine,[28][29][30] with higher doses having greater effect.[29][30] Data are conflicting for whether statins reduce risk of kidney failure.[28] Statins, including atorvastatin, before heart surgery do not prevent acute kidney injury.[31]

Prior to contrast medium (CM) administration, pre-treatment with atorvastatin therapy can reduce the risk of contrast-induced acute kidney injury (CI-AKI) in patients with pre-existing chronic kidney disease (CKD) (eGFR < 60mL/min/1.73m2) who undergo interventional procedures such as cardiac catheterisation, coronary angiography (CAG) or percutaneous coronary intervention (PCI).[32][33][34] A meta-analysis of 21 RCTs confirmed that high dose (80 mg) atorvastatin therapy is more effective than regular dose or low dose statin therapy at preventing CI-AKI.[32] Atorvastatin therapy can also help to prevent in-hospital dialysis post CM administration, however there is no evidence that it reduces all-cause mortality associated with CI-AKI.[32][33] Overall, the evidence concludes that statin therapy, irrespective of the dose, is still more effective than no treatment or placebo at reducing the risk of CI-AKI.[32][33][34][35]

Administration

Statins (predominantly simvastatin) have been evaluated in clinical trials in combination with fibrates to manage dyslipidemia in patients who also have type 2 diabetes, and a high cardiovascular disease risk, however, there is limited clinical benefit noted for most cardiovascular outcomes [36][37]

While many short half-lives statin medications should be taken in the evening for optimal effect, atorvastatin tablets can be taken at any time of day due to its long half-life profile, as long as it is taken at the same time every day. This also potentially ensures better patient compliance. Some studies found evening dose of both short and long half-life statins were significantly superior to morning dose for lowering LDL-C.[38][39][40][41]

Specific populations

  • Geriatric: Plasma concentrations of atorvastatin in healthy elderly subjects are higher than those in young adults, and clinical data suggests a greater degree of LDL-lowering at any dose for people in the population as compared to young adults.[3]
  • Pediatric: Pharmacokinetic data is not available for this population.[3]
  • Gender: Plasma concentrations are generally higher in women than in men, but there is no clinically significant difference in the extent of LDL reduction between men and women.[3]
  • Kidney impairment: Kidney disease has no statistically significant influence on plasma concentrations of atorvastatin and dose adjustment considerations should only be made in context of the patient's overall health.[42][unreliable medical source][43][unreliable medical source]
  • Hemodialysis: Although there has been moderate-to-high quality of evidence to show the lack of clear and significant clinical benefits of statins (including atorvastatin at a dose of 20mg) minimizing non-fatal myocardial infarction, stroke, and cardiovascular mortality in adult patients on haemodialysis (including those with diabetes and/or pre-existing cardiovascular diseases) despite the clinically relevant reduction in total/LDL cholesterol levels,[44][unreliable medical source][45] there is evidence that haemodialysis patients who received moderate intensity statin therapy had a lower risk of all-cause mortality.[46]
  • However, data (post hoc analysis) on atorvastatin has revealed that it may still be beneficial in reducing combined cardiac events, cardiac and all-cause mortality in those with a higher baseline LDL cholesterol >3.75 mmol/L.[47][unreliable medical source] While the SHARP study suggested that LDL cholesterol-lowering treatments (e.g. statin/ezetimibe combination) are effective in reducing the risks of major atherosclerotic events in the CKD patients including those on dialysis, the subgroup analysis of the haemodialysis patients had revealed no significant benefits.[48][unreliable medical source] Whether or not haemodialysis had any impact on the statin levels was not specifically addressed in these major trials.
  • Hepatic Impairment: Increased drug levels can be seen in patients with advanced cirrhosis; specific precaution should be used in patients with chronic alcoholic liver disease.[3] Despite these concerns, a 2017 systematic review and analysis of available evidence has shown that statins, such as atorvastatin, are relatively safe to use in stable, asymptomatic cirrhosis and may even reduce the risk of liver disease progression and death.[49]

Contraindications

  • Active liver disease: cholestasis, hepatic encephalopathy, hepatitis, and jaundice
  • Pregnancy: Atorvastatin is unlikely to cause fetal anomalies but may be associated with low birth weight and preterm labour.[50]
  • Breastfeeding: Small amounts of other statin medications have been found to pass into breast milk, although atorvastatin has not been studied, specifically.[3] Due to risk of disrupting a breastfeeding infant's metabolism of lipids, atorvastatin is not regarded as compatible with breastfeeding.[51]
  • Markedly elevated
    antifungals.[3]

Side effects

Major

  • Type 2 diabetes is observed in a small number of people, and is an uncommon class effect of all statins.[54][55][56] It appears it may be more likely in people who were already at a higher risk of developing diabetes before starting a statin due to multiple risk factors, for example raised fasting glucose levels.[57] However, the benefits of statin therapy in preventing fatal and non-fatal stroke, fatal coronary heart disease, and non-fatal myocardial infarction are significant.[18] For most people the benefits of statin therapy far outweigh the risk of developing diabetes.[58] A 2010 meta-analysis demonstrated that every 255 people treated with a statin for four years – produced a reduction of 5.4 major coronary events and induced only one new case of diabetes.[58]
  • In some case and clinical studies mild muscle pain or weakness have been reported (around 3%), compared to a placebo.[59][60] However, this increase was not related to statin therapy in 90% of cases in a large meta-analysis of randomized controlled trials.[60] In patients taking higher statin doses, a similarly low increase in muscle pain and weakness was present (5%) with no clear evidence of a dose-response relationship. Duration of treatment with atorvastatin is unlikely to increase the risk of muscle-related side effects as most occur within the first year of treatment, after which the risk is not increased further.[60] The known cardiovascular benefits of atorvastatin over time outweigh the low risk of muscle-related side effects.[61][60]
  • There is also an increased risk of statin-induced rhabdomyolysis when statins are taken over the long term.[62]
  • Persistent liver enzyme abnormalities (usually elevated in hepatic transaminases) have been documented.
    hepatic function be assessed with laboratory tests before beginning atorvastatin treatment and repeated periodically as clinically indicated - usually a clinicians' judgement. Package inserts for this statin recommend actions should liver abnormalities be detected, ultimately, this is the judgment of the prescribing physician.[3]

Common

The following have been shown to occur in 1–10% of people taking atorvastatin in clinical trials:

Other

Cognitive

There have been rare reports of reversible memory loss and confusion with all statins, including atorvastatin; however, there has not been enough evidence to associate statin use with cognitive impairment, and the risks for cognition are likely outweighed by the beneficial effects of adherence to statin therapy on cardiovascular and cerebrovascular disease.[68][69][70][71]

Pancreatitis

There is some evidence that atorvastatin use may increase the risk of acute pancreatitis, in people who are already at a higher risk.[72][73] However, there is also evidence that atorvastatin use decreases the risk of acute pancreatitis in people with mild to moderate hypertriglyceridemia, by lowering triglyceride levels.[73]

Erectile dysfunction

Statins seem to have a positive effect on erectile dysfunction.[74][75]

Interactions

Fibrates are a class of drugs that can be used for severe or refractory mixed hyperlipidaemia in combination with statins or as monotherapy. Several studies suggest that the concomitant therapy of atorvastatin with drugs from the fibrate drug class (such as gemfibrozil, fenofibrate) can increase the risk of myopathy and rhabdomyolysis,[76][77][78][79] however other studies have found this to not be the case. [80][81]

Co-administration of atorvastatin with one of

Oral contraceptives increased AUC values for norethisterone and ethinylestradiol; these increases should be considered when selecting an oral contraceptive for a woman taking atorvastatin.[3]

Antacids can rarely decrease the plasma concentrations of statin medications, but do not affect the LDL-C-lowering efficacy.[85]

Niacin also is proved to increase the risk of myopathy or rhabdomyolysis.[53]

Some statins may also alter the concentrations of other medications, such as warfarin or digoxin, leading to alterations in effect or a requirement for clinical monitoring.[53] The increase in digoxin levels due to atorvastatin is a 1.2 fold elevation in the area under the curve (AUC), resulting in a minor drug-drug interaction. The American Heart Association states that the combination of digoxin and atorvastatin is reasonable.[86] In contrast to some other statins, atorvastatin does not interact with warfarin concentrations in a clinically meaningful way (similar to pitavastatin).[86]

Vitamin D supplementation lowers atorvastatin and active metabolite concentrations, yet synergistically reduces LDL and total cholesterol concentrations.[87]

Grapefruit juice components are known inhibitors of intestinal CYP3A4. Drinking grapefruit juice with atorvastatin may cause an increase in Cmax and area under the curve (AUC). This finding initially gave rise to concerns of toxicity, and in 2000, it was recommended that people taking atorvastatin should not consume grapefruit juice "in an unsupervised manner."[88] Small studies (using mostly young participants) examining the effects of grapefruit juice consumption on mainly lower doses of atorvastatin have shown that grapefruit juice increases blood levels of atorvastatin, which could increase the risk of adverse effects.[89][90][91] No studies assessing the impact of grapefruit juice consumption have included participants taking the highest dose of atorvastatin (80 mg daily),[89][90][91] which is often prescribed for people with a history of cardiovascular disease (such as heart attack or ischaemic stroke) or in people at high risk of cardiovascular disease. People taking atorvastatin should consult with their doctor or pharmacist before consuming grapefruit juice, as the effects of grapefruit juice consumption on atorvastatin will vary according to factors such as the amount and frequency of juice consumption in addition to differences in juice components, quality and method of juice preparation between different batches or brands.[92]

A few cases of myopathy have been reported when atorvastatin is given with colchicine.[3]

Mechanism of action

Main article: Statin

As with other statins, atorvastatin is a competitive

HDL-cholesterol
.

In people with

thrombotic stroke recurrence prevention.[95][96][97]

Pharmacodynamics

The liver is the primary site of action of atorvastatin, as this is the principal site of both cholesterol synthesis and LDL clearance. It is the dosage of atorvastatin, rather than systemic medication concentration, which correlates with extent of LDL-C reduction.[3] In a Cochrane systematic review the dose-related magnitude of atorvastatin on blood lipids was determined. Over the dose range of 10 to 80 mg/day total cholesterol was reduced by 27.0% to 37.9%, LDL cholesterol by 37.1% to 51.7% and triglycerides by 18.0% to 28.3%.[98]

Pharmacokinetics

Absorption

Atorvastatin undergoes rapid absorption when taken orally, with an approximate time to maximum plasma concentration (

first-pass metabolism, which is the main cause for the low systemic availability. Administration of atorvastatin with food produces a 25% reduction in Cmax (rate of absorption) and a 9% reduction in AUC (extent of absorption), although food does not affect the plasma LDL-C-lowering efficacy
of atorvastatin. Evening dose administration is known to reduce the Cmax and AUC by 30% each. However, time of administration does not affect the plasma LDL-C-lowering efficacy of atorvastatin.

Distribution

The mean volume of distribution of atorvastatin is approximately 381 L. It is highly protein bound (≥98%), and studies have shown it is likely secreted into human breastmilk.

Metabolism

Atorvastatin

beta-oxidation metabolites. The ortho- and parahydroxylated metabolites are responsible for 70% of systemic HMG-CoA reductase activity. The ortho-hydroxy metabolite undergoes further metabolism via glucuronidation. As a substrate for the CYP3A4 isozyme, it has shown susceptibility to inhibitors and inducers of CYP3A4 to produce increased or decreased plasma concentrations, respectively. This interaction was tested in vitro with concurrent administration of erythromycin
, a known CYP3A4 isozyme inhibitor, which resulted in increased plasma concentrations of atorvastatin. It is also an inhibitor of cytochrome 3A4.

Excretion

Atorvastatin is primarily eliminated via

biliary excretion, with less than 2% recovered in the urine. Bile elimination follows hepatic and/or extrahepatic metabolism. There does not appear to be any entero-hepatic recirculation. Atorvastatin has an approximate elimination half-life of 14 hours. Noteworthy, the HMG-CoA reductase inhibitory activity appears to have a half-life of 20–30 hours, which is thought to be due to the active metabolites. Atorvastatin is also a substrate of the intestinal P-glycoprotein efflux transporter, which pumps the medication back into the intestinal lumen during medication absorption.[53]

In hepatic insufficiency, plasma concentrations of atorvastatin are significantly affected by concurrent liver disease. People with Child-Pugh Stage A liver disease show a four-fold increase in both Cmax and AUC. People with Child Pugh stage B liver disease show a 16-fold increase in Cmax and an 11-fold increase in AUC.

Geriatric people (>65 years old) exhibit altered pharmacokinetics of atorvastatin compared to young adults, with mean AUC and Cmax values that are 40% and 30% higher, respectively. Additionally, healthy elderly people show a greater pharmacodynamic response to atorvastatin at any dose; therefore, this population may have lower effective doses.[3]

Pharmacogenetics

Several genetic

polymorphisms may be linked to an increase in statin-related side effects with single nucleotide polymorphisms (SNPs) in the SLCO1B1 gene showing a 45 fold higher incidence of statin related myopathy[99]
than people without the polymorphism.

There are several studies showing genetic variants and variable response to atorvastatin.[100][101] The polymorphisms that showed genome wide significance in Caucasian population were the SNPs in the apoE region; rs445925,[100] rs7412,[100][101] rs429358[101] and rs4420638[100] which showed variable LDL-c response depending on the genotype when treated with atorvastatin.[100][101] Another genetic variant that showed genome wide significance in Caucasians was the SNP rs10455872 in the LPA gene that lead to higher Lp(a) levels which cause an apparent lower LDL-c response to atorvastatin.[100] These studies were in Caucasian population, more research with a large cohort need to be conducted in different ethnicities to identify more polymorphisms that can affect atorvastatin pharmacokinetics and treatment response.[100]

Chemical synthesis

Atorvastatin synthesis in commercial production (process) chemistry. The key step of establishing this medication's stereocenters, through initial use of an inexpensive natural product (chiral pool approach).
Atorvastatin synthesis during discovery chemistry. The key step of establishing stereocenters, using of a chiral ester auxiliary approach.

The first synthesis of atorvastatin at Parke-Davis that occurred during drug discovery was racemic followed by chiral chromatographic separation of the enantiomers. An early enantioselective route to atorvastatin made use of an ester chiral auxiliary to set the stereochemistry of the first of the two alcohol functional groups via a diastereoselective aldol reaction.[102][103]

Once the compound entered

pre-clinical development, process chemistry developed a cost-effective and scalable synthesis.[102] In atorvastatin's case, a key element of the overall synthesis was ensuring stereochemical purity in the final drug substance, and hence establishing the first stereocenter became a key aspect of the overall design. The final commercial production of atorvastatin relied on a chiral pool approach, where the stereochemistry of the first alcohol functional group was carried into the synthesis—through the choice of isoascorbic acid, an inexpensive and easily sourced plant-derived natural product.[102][104]

The atorvastatin calcium complex involves two atorvastatin ions, one calcium ion and three water molecules.[105]

History

Mevacor). Mevacor, which was first marketed in 1987, was the industry's first statin and Merck's synthetic version – simvastatin – was in the advanced stages of development.[107] Nevertheless, Bruce Roth and his bosses, Roger Newton and Ronald Cresswell, in 1985, convinced company executives to move the compound into expensive clinical trials. Early results comparing atorvastatin to simvastatin demonstrated that atorvastatin appeared more potent and with fewer side effects.[107]

In 1994, the findings of a Merck-funded study were published in The Lancet concluding the efficacy of statins in lowering cholesterol proving for the first time not only that a "statin reduced 'bad' LDL cholesterol but also that it led to a sharp drop in fatal heart attacks among people with heart disease."[107][111]

In 1996, Warner-Lambert entered into a co-marketing agreement with Pfizer to sell Lipitor, and in 2000, Pfizer acquired Warner-Lambert for $90.2 billion.[112][102][108][109] Lipitor was on the market by 1996.[110][113] By 2003, Lipitor had become the best selling pharmaceutical in the United States.[106] From 1996 to 2012, under the trade name Lipitor, atorvastatin became the world's best-selling medication of all time, with more than $125 billion in sales over approximately 14.5 years.[114] and $13 billion a year at its peak,[115] Lipitor alone "provided up to a quarter of Pfizer Inc.'s annual revenue for years."[114]

Pfizer's patent on atorvastatin expired in November 2011.[116]

Society and culture

Economics

Atorvastatin is relatively inexpensive.

Patient Protection and Affordable Care Act (PPACA) in the United States, health plans may cover the costs of atorvastatin 10 mg and 20 mg for adults aged 40–75 years based on United States Preventive Services Task Force (USPSTF) recommendations.[117][118][119] Some plans only cover other statins.[120][121]

Brand names

Pack and tablet of atorvastatin (Lipitor) 40mg

Atorvastatin calcium tablets are sold under the brand name Lipitor.

atorvastatin/amlodipine.[123]

Pfizer's U.S. patent on Lipitor expired on 30 November 2011.[124] Initially, generic atorvastatin was manufactured only by Watson Pharmaceuticals and India's Ranbaxy Laboratories. Prices for the generic version did not drop to the level of other generics—$10 or less for a month's supply—until other manufacturers began to supply the medication in May 2012.[125]

In other countries, atorvastatin calcium is made in tablet form by generic medication makers under various brand names including Atoris, Atorlip, Atorva, Atorvastatin Teva, Atorvastatina Parke-Davis, Avas, Cardyl, Liprimar, Litorva, Mactor, Orbeos, Prevencor, Sortis, Stator, Tahor, Torid, Torvacard, Torvast, Totalip, Tulip, Xarator, and Zarator.[126][127] Pfizer also makes its own generic version under the name Zarator.[128]

Medication recalls

On 9 November 2012, Indian drugmaker Ranbaxy Laboratories Ltd. voluntarily recalled 10-, 20- and 40-mg doses of its generic version of atorvastatin in the United States.[129][130][131] The lots of atorvastatin, packaged in bottles of 90 and 500 tablets, were recalled due to possible contamination with very small glass particles similar to the size of a grain of sand (less than 1 mm in size). The FDA received no reports of injury from the contamination.[129] Ranbaxy also issued recalls of bottles of 10-milligram tablets in August 2012 and March 2014, due to concerns that the bottles might contain larger, 20-milligram tablets and thus cause potential dosing errors.[132][133]

References

  1. ^ a b "Atorvastatin (Lipitor) Use During Pregnancy". Drugs.com. 3 February 2020. Archived from the original on 4 December 2019. Retrieved 26 February 2020.
  2. ^ "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
  3. ^ a b c d e f g h i j k l m n o p q r "Lipitor- atorvastatin calcium tablet, film coated". DailyMed. Archived from the original on 26 November 2020. Retrieved 26 February 2020.
  4. ^ a b c d e f g h i "Atorvastatin Calcium Monograph for Professionals". Drugs.com. AHFS. Archived from the original on 25 October 2010. Retrieved 23 December 2018.
  5. ISBN 9783527607495. Archived
    from the original on 12 January 2023. Retrieved 10 May 2020.
  6. hdl:10665/345533
    . WHO/MHP/HPS/EML/2021.02.
  7. ^
    ISBN 978-0-7020-5515-7. Archived
    from the original on 26 February 2023. Retrieved 27 June 2022.
  8. ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
  9. ^ "Atorvastatin - Drug Usage Statistics". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
  10. ^ "Atorvastatin Calcium". American Society of Health-System Pharmacists. Archived from the original on 25 October 2010. Retrieved 3 April 2011.
  11. ^
    PMID 12915827
    .
  12. PMID 16533939
    .
  13. PMID 7749881
    .
  14. PMID 8531308
    .
  15. PMID 16908955
    .
  16. PMID 9301631
    .
  17. ISBN 978-0-9757919-2-9
    .
  18. ^
    S2CID 9409142
    .
  19. PMID 12829554
    .
  20. PMID 9603539
    .
  21. PMID 9514454
    .
  22. S2CID 28885209
    .
  23. PMID 17065671
    .
  24. S2CID 27148191
    .
  25. ^
    PMID 26385210
    .
  26. ^
    PMID 22085316
    .
  27. ^
    PMID 14996776
    .
  28. ^
    PMID 26905361
    .
  29. ^
    PMID 25001155
    .
  30. ^
    S2CID 6575836
    .
  31. PMID 28242291
    .
  32. ^
    S2CID 52875826
    .
  33. ^
    S2CID 3295220. Archived
    (PDF) from the original on 30 November 2020. Retrieved 9 May 2020.
  34. ^
    PMID 32150109
    .
  35. PMID 30464400
    .
  36. S2CID 40744740
    .
  37. PMID 20228404
    .
  38. PMID 11368702
    .
  39. PMID 15249516
    .
  40. PMID 35512427
    .
  41. PMID 28826569. Archived
    (PDF) from the original on 13 November 2023. Retrieved 26 May 2023.
  42. PMID 12686673
    .
  43. S2CID 752038
    .
  44. PMID 16034009
    .
  45. PMID 19332456
    .
  46. PMID 32089045
    .
  47. PMID 21493741
    .
  48. PMID 21663949
    .
  49. PMID 28479502
    .
  50. PMID 34967881
    .
  51. ^ "TOXNET". toxnet.nlm.nih.gov. U.S. National Library of Medicine. Archived from the original on 12 June 2018. Retrieved 29 May 2018.
  52. S2CID 12838555. Archived
    (PDF) from the original on 26 February 2023. Retrieved 28 December 2020.
  53. ^
    S2CID 8759303
    .
  54. S2CID 22626629
    .
  55. S2CID 11544414
    .
  56. PMID 23109518
    .
  57. S2CID 64660561
    .
  58. ^
    PMID 21067804
    .
  59. PMID 36049498
    .
  60. ^
    PMID 15755765
    .
  61. PMID 24655568
    .
  62. PMID 24799748
    .
  63. PMID 17159064
    .
  64. PMID 12972104
    .
  65. S2CID 2955398
    .
  66. S2CID 19151464
    .
  67. PMID 26577796
    .
  68. PMID 25575908
    .
  69. PMID 29643479
    .
  70. PMID 31753200
    .
  71. ^ "Atorvastatin: A medicine used to lower cholesterol". 3 January 2019. Archived from the original on 7 November 2021. Retrieved 7 November 2021.
  72. PMID 26886597
    .
  73. ^
    PMID 22910758. Archived
    (PDF) from the original on 23 January 2022. Retrieved 23 January 2023.
  74. PMID 24684744
    .
  75. PMID 24628781
    .
  76. S2CID 22429669
    .
  77. PMID 9929751
    .
  78. S2CID 23785176
    .
  79. ^ "Independent, reliable, relevant and respected". Therapeutic Guidelines. Archived from the original on 8 May 2021. Retrieved 9 May 2021.
  80. S2CID 9148062
    .
  81. PMID 12843167
    .
  82. S2CID 26375921
    .
  83. S2CID 35917120
    .
  84. S2CID 8715786
    .
  85. PMID 15901588
    .
  86. ^
    S2CID 19169932
    .
  87. S2CID 23604512
    .
  88. PMID 10994829
    .
  89. ^
    PMID 16236039
    .
  90. ^
    PMID 21501216
    .
  91. ^
    S2CID 8103490
    .
  92. doi:10.18773/austprescr.2006.026. Archived
    from the original on 27 August 2021. Retrieved 10 May 2020.
  93. ^
    S2CID 212408322
    .
  94. ^
    S2CID 28738671
    .
  95. PMID 22581818
    .
  96. PMID 16899775
    .
  97. S2CID 195685309
    .
  98. PMID 25760954
    .
  99. PMID 24810685
    .
  100. ^
    PMID 22368281
    .
  101. ^
    S2CID 5928092
    .
  102. ^
    PMID 12516521
    .
  103. PMID 1992137
    .
  104. ISBN 978-0-471-21480-9
    .
  105. ^ "Fig. 1. Chemical structure of Atorvastatin Calcium". Researchgate.net. Archived from the original on 21 August 2022. Retrieved 25 May 2022.
  106. ^ a b c Simons J (20 January 2003). "The $10 Billion Pill Hold the fries, please. Lipitor, the cholesterol-lowering medication, has become the bestselling pharmaceutical in history. Here's how Pfizer did it". Fortune.
  107. ^ a b c d Andrew J (28 November 2009). "The fall of the world's best-selling drug". Financial Times. Archived from the original on 10 December 2022. Retrieved 24 November 2015.
  108. ^ a b US patent 4681893, Roth BD, "Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis", issued 21 July 1987 
  109. ^ a b Hoefle ML (2000). "The Early History of Parke-Davis and Company" (PDF). Bull. Hist. Chem. 25 (1): 28–34. Archived (PDF) from the original on 20 September 2018. Retrieved 12 March 2020.
  110. ^ a b Petersen M (8 February 2000). "Pfizer Gets Its Deal to Buy Warner-Lambert for $90.2 Billion". The New York Times. Archived from the original on 15 December 2018. Retrieved 18 February 2017.
  111. S2CID 5965882
    .
  112. ^ Winslow R (24 January 2000). "The Birth of a Blockbuster: Lipitor's Route out of the Lab". The Wall Street Journal. Archived from the original on 7 April 2019. Retrieved 26 October 2011.
  113. ^ "Approval Letter" (PDF). U.S. Food and Drug Administration (FDA). Archived (PDF) from the original on 24 September 2020. Retrieved 21 June 2019.
  114. ^ a b "Lipitor becomes world's top-selling drug". Crain's New York Business via Associated Press. 28 December 2011. Archived from the original on 29 December 2011. Retrieved 24 November 2011.
  115. ^ "The Vindication of Roger Newton". Ann Arbor Observer. April 2020. Archived from the original on 17 September 2021. Retrieved 19 August 2022.
  116. ^ "Lipitor loses patent, goes generic". CNN. 30 November 2011. Archived from the original on 18 January 2017. Retrieved 18 November 2012.
  117. ^ "PPACA no cost-share preventive medications" (PDF). Cigna. Archived (PDF) from the original on 2 December 2020. Retrieved 30 March 2020.
  118. ^ "Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Recommendation Statement". American Family Physician. 95 (2). 15 January 2017. Archived from the original on 3 August 2020. Retrieved 31 March 2020.
  119. ^ "Recommendation: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication". United States Preventive Services Taskforce. 15 November 2016. Archived from the original on 9 May 2022. Retrieved 7 May 2022.
  120. ^ "SignatureValue Zero Cost Share Preventive Medications PDL" (PDF). Uhc.com. September 2021. Archived (PDF) from the original on 5 February 2022. Retrieved 25 May 2022.
  121. ^ "Affordable Care Act Implementation FAQs - Set 12". CMS. 22 April 2013. Archived from the original on 5 May 2022. Retrieved 7 May 2022.
  122. ^ Medical Product Reviews. "Atorvastatin Calcium (Lipitor Tablets) – Uses, Dosage and Side Effects". Archived from the original on 6 October 2013. Retrieved 3 May 2012.
  123. ^ News Medical (March 2010). "Lipitor – What is Lipitor?". Archived from the original on 8 March 2012. Retrieved 3 May 2012.
  124. ^ "Pfizer's 180-Day War for Lipitor". PM360. 8 August 2013. Archived from the original on 12 April 2020. Retrieved 12 April 2020.
  125. ^ "Price to UK for 28 tablets from £3.25 (10mg) to £10.00 (80mg)". National Health Service. June 2012. Archived from the original on 20 September 2012. Retrieved 31 July 2012.
  126. ^ "Atorvastatin international". Drugs.com. 4 May 2020. Archived from the original on 3 August 2020. Retrieved 10 May 2020.
  127. ^ "Lipitor referral". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 20 October 2020. Retrieved 10 May 2020.
  128. ^ Rapley L (31 May 2012). "Atorvastatin sole funding announced". PharmacyToday.co.nz. Archived from the original on 17 July 2014. Retrieved 16 July 2014.
  129. ^ a b "FDA Statement on Ranbaxy Atorvastatin Recall". U.S. Food and Drug Administration (FDA). 30 December 2012. Archived from the original on 19 April 2014. Retrieved 19 April 2014.
  130. ^ Loftus P, Weaver C (23 November 2012). "Ranbaxy Recalls Generic Lipitor Doses". The Wall Street Journal. Archived from the original on 17 May 2021. Retrieved 6 March 2021.
  131. ^ Johnson LA (24 November 2012). "Ranbaxy recalls generic Lipitor doses". The Boston Globe. Associated Press. Archived from the original on 29 December 2017. Retrieved 29 December 2017.
  132. ^ Loftus P (7 March 2014). "Ranbaxy Recalls More Than 64,000 Bottles of Generic Lipitor in U.S.". The Wall Street Journal. Archived from the original on 21 June 2019. Retrieved 21 June 2019.
  133. ^ Siddiqui Z, Sikka K (8 March 2014). "Indian drugmaker Ranbaxy recalls more than 64,000 bottles of its generic version of Lipitor". The Washington Post. Archived from the original on 29 December 2017. Retrieved 29 December 2017.

Further reading

Retrieved from "https://en.wikipedia.org/w/index.php?title=Atorvastatin&oldid=1219732309"